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Abstract 
5-Fluorouracil though recommended as a chemotherapeutic agent for 
colorectal cancer, suffers from severe systemic toxicity and so needs 
site-specific delivery. Objective of present investigation is to design 
slow release enteric coated solid formulations to avoid drug release 
in stomach and upper small intestine but slowly to build up required 
drug concentration in the colon. Chitosan microspheres were 
prepared by emulsification method using gluteraldehyde as cross 
linking agent.   The microspheres were then coated with Eudragit S – 
100 by emulsion solvent evaporation method.  The coated 
microspheres were characterized for particle size, entrapment 
efficiency and surface characteristics. In-vitro drug release profile 
was studied by changing pH media as per USP protocol and the data 
was subjected to kinetic interpretations. The optimized microspheres 
showed particle size in the range of 62 to 65 μm with 65 ± 2% drug 
entrapment. Eudragit coated chitosan microspheres showed particle 
size increase upto 390 ± 2 μm with nearly spherical shape and 
smooth surface.  In vitro drug release profile of uncoated 
microspheres was typical like conventional dosage forms with 38 %, 
62 % and 88 % drug release at the end of 2 hrs, 6 hrs and 10 hrs 
respectively. Coated microspheres showed no drug release in SGF 
(2hrs), negligible release (8 %) in 6hrs but substantial release of 95% 
in 24 hours in simulated colon media. Drug distribution in GI 
following oral administration of coated microspheres in wistar rats 
showed 84% of the drug accumulation in colon.   
Keywords: 5-FU; colon-targeting; chitosan; microspheres; Eudragit 
S-100. 
 
Introduction 
Colorectal cancer is one of the major causes of 
mortality and morbidity in industrialized nations. 
Treatment for colorectal cancer can be by any of 
the 3 modalities like surgery, radiation therapy or 
chemotherapy. Chemotherapy, however, is 
invariably used as an immediate treatment 
method alone or with surgery or radiotherapy. 
Out of many chemotherapeutics, 5-fluorouracil 
(5-FU) has been approved for use against  
 
colorectal cancer. IV administration of 5-FU has 
shown toxicities with complications in 
gastrointestinal, hematological, neural, cardiac 
and dermatological areas [1]. Delivery of 5 – FU 
to colon as site specific delivery in the form of 
microspheres may reduce the complications of 
toxicity, thereby, providing drug in 
therapeutically effective concentrations treating 
colorectal cancer.  
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Colon drug delivery has a number of implications 
in the field of pharmacotherapy. Diseases like 
inflammatory bowel disease (IBD) are treated 
effectively by delivering bioactive agents to 
colon through targeting [2]. Other colonic 
disorders like amoebiasis, crohn’s disease, 
ulcerative colitis and colorectal cancer are also 
treated effectively by delivering bioactive agents 
locally, using coated microspheres which 
minimize release / absorption of drug in stomach 
and small intestine but deliver drugs to the large 
bowel [3]. Colon drug delivery has lot of 
challenges like minimizing degradation of drug in 
upper GI tract, protection of peptide drugs from 
hydrolysis and enzymatic degradation in 
duodenum and jejunum etc.  A carefully designed 
colon therapeutic system could achieve maximum 
drug release in colon and elicit high activity with 
minimum systemic side effects. The specific drug 
release in colon provides a sufficient time interval 
between administration and onset of action which 
proves to be useful in treating chronic diseases 
such as asthma and arthritis [4].   
 
Some strategies currently available for colon 
targeting are prodrug formulation, use of coating 
techniques to pH sensitive polymers, timed 
release systems, osmotic systems, pressure 
controlled drug delivery systems and by utilizing 
colon – specific biodegradable polymers [5]. 
Among the above methods, colon specific drug 
delivery systems developed are in majority 
utilizing the advantage of luminal pH in the ileum 
and / or microbial enzymes in the colon. Several 
biodegradable polymers which can be 
metabolized by colonic bacteria are used to 
prepare carrier systems like tablets and 
particulate delivery systems like microparticles / 
microspheres.  
 
Polysaccharides belong to one such class of 
biodegradable materials which are normally 
metabolized in the colon by bacterial enzymes. 
This approach is exploited to deliver various 
drugs using polysaccharides such as pectin, 
alginate, guargum, amylase, inulin, dextran, 
chitosan, chondroitin sulphate etc. Large number 
of derivatizable groups present on these natural 
polymers makes them an ideal carrier system. 
Varying compositions, wide range of molecular 
weights, low toxicity, biodegradability and high 
stability makes them more appealing. Apart from 
all these, they are also approved by federal 
authorities for use as pharmaceutical excipients.      
 
In the present investigation, cross linked chitosan 
microspheres of 5 – fluoro uracil were prepared 
and studied for their suitability to colon specific 
delivery. Polysaccharide based systems undergo 
enzymatic degradation in colon and chitosan is 
selected here as the matrix material to deliver the 
drug to colon. Eudragit S-100 is used as an 
enteric coating material to keep the microspheres 
intact and not to release the drug in stomach and 
or upper intestine. In contrast to single unit 
systems like tablets for oral use, multiple unit 
systems like microspheres are administered here 
as they show marked advantages like spreading 
over a large area in colon and avoiding exposure 
of high drug concentrations to a confined part of 
colonic mucosa. This also prolongs drug mean 
residence time in colon [6-7].  
 
In-vitro drug release experiments in colonic 
media were conducted and kinetic parameters 
were calculated to assess the specificity of drug 
to release in colon [8]. In-vivo drug distribution 
study in GI tract was also conducted in wister rats 
model to confirm the suitability of the 
formulation for site specific delivery of 5-FU to 
colon. 
 
Materials and Methods 
Materials 
5- Fluorouracil was kindly provided as a gift 
sample by Zydus Cadila, Ahmedabad. Chitosan 
was obtained from Central Institute of Fisheries 
and Technology, Cochin.  Eudragit S 100 was a 
gift sample from Rohm Pharma, Germany. 
Hydrochloric acid, Disodium hydrogen 
phosphate, Potassium dihydrogen phosphate, 
methanol and dichloromethane were purchased 
from S.D. Chemicals, Boiser.  
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Reagents: Simulated Gastric Fluid, pH 1.2 (SGF) 
and Phosphate Buffered Saline, pH 7.4 (SIF) 
were prepared as per Indian Pharmacopoeia. 
Simulated Intestinal Fluid, pH 5.0 was prepared 
by dissolving specified quantity of KH2PO4 and 
Na2HPO4.2H2O and then adjusting the pH to 5.0 
with 1.0 N NaOH. Simulated Colon Media 
(SCM) containing 2% rat cecal content was 
prepared by the method reported by Van den 
Mooter et al [9].   
 
Methods 
Preparation of cross linked chitosan 
Microspheres 
 
Microspheres of 5 – fluorouracil were prepared 
with different concentrations of chitosan (Table 
1) by emulsion method using gluteraldehyde as 
cross linking agent as reported by Thanoo et.al. 
[10]. Chitosan was dissolved in 5 % aqueous 
acetic acid solution and 5 – FU was dispersed in 
this solution by stirring. The above mixture was 
dispersed in liquid paraffin (1:1) containing 2 % 
span 80 and subjected to stirring using high speed 
stirrer at 2000 rpm for 4 hours at room 
temperature. 0.5 ml gluteraldehyde was added 
after 10 minutes of stirring followed by a second 
fraction of 0.5 ml gluteraldehyde after 1 hour of 
stirring. After 4 hours, the formed microspheres 
were centrifuged and washed several times with n 
– hexane to remove traces of liquid paraffin. The 
microspheres were then suspended in 5 % w / v 
solution of sodium bisulphate and further stirred 
on a magnetic stirrer for 10 minutes to remove 
residual gluteraldehyde. The washed 
microspheres were dried in vacuum dessicator for 
48 hours before subjecting to further studies. 
 
Table 1: Preparation of cross linked chitosan Microspheres  
Batch 
No. 
Drug: 
Poly
mer 
w/w 
Emulsi
fier 
conc. 
(ml) 
Particle 
size (μm) 
Entrapment 
efficiency 
CC 1 A 1:2 0.75 72.21 ± 1.93 37.18 ± 0.65 
CC 1 B 1:2 1.00 65.22 ± 0.98 36.08 ± 1.17 
CC 1 C  1:2 1.25 61.22 ± 1.28 34.22 ± 1.07 
CC 2 A 1:3 0.75 80.02 ± 1.80 46.50 ± 0.82 
CC 2 B 1:3 1.00 74.15 ± 0.84 44.19 ± 0.97 
CC 2 C  1:3 1.25 72.05 ± 1.12 43.29 ± 0.97 
CC 3 A 1:4 0.75 98.91 ± 1.20 59.70 ± 1.14 
CC 3 B 1:4 1.00 93.41 ±  
1.43 
58.40 ± 1.34 
CC 3 C  1:4 1.25 90.41 ± 1.83 55.44 ± 1.34 
CC 4 A 1:5 0.75 110.68 ± 
1.41 
66.04 ± 0.97 
CC 4 B 1:5 1.00 105.51 ±  
0.98 
65.00 ± 1.15 
CC 4 C  1:5 1.25 101.21 ± 
1.87 
62.87 ± 0.11 
 
Coating of Cross linked Chitosan 
microspheres  
The optimized chitosan microspheres were coated 
with Eudragit S – 100 by emulsion solvent 
evaporation method [11]. The microspheres were 
suspended in 10 ml of organic solvent 
(acetone:ethanol::2:1) in which different 
strengths of Eudragit S – 100 was previously 
dissolved  to give core coating ratio between 1:5 
and 1:10. The above organic dispersion was then 
emulsified in 100 ml of liquid paraffin containing 
2 % span 80 and stirred at 1000 rpm for 4 hours 
at room temperature to remove the solvents by 
evaporation. The eudragit coated microspheres 
were separated, rinsed with n – Hexane to remove 
residual traces of liquid paraffin, dried and stored 
in vacuum desiccators.   
 
Entrapment Efficiency 
Drug loaded chitosan microspheres were 
dispersed in methanol and kept for digestion with 
continuous stirring upto 24 hours. The 
microspheres were then centrifuged at 1000 rpm 
for 10 minutes to remove any insoluble solids, the 
supernatant layer decanted and filtered. The drug 
content was determined by using UV – Visible 
Spectrophotometer at 266 nm in methanol media.  
 
Entrapment efficiency was calculated using the 
following formula, 
 
Entrapment Efficiency = (Entrapped drug / total drug) X 100   Eq- 1 
 
Yield of Microspheres 
Microspheres recovered at the end of the 
preparation were weighed and the yield was 
calculated as % of total theoretical weight of the 
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materials taken for the preparation. The yield of 
microspheres was calculated as below: 
% Yield = (Practical yield / theoretical yield) X 100       Eq- 2 
 
Particle Size Analysis 
The mean particle size of prepared microspheres 
was determined by a laser light scattering 
technique using Mastersizer (Malvern 
Instruments, London, UK) operating at a beam 
length of 2.40 mm and range of lens at 300 mm. 
 
Surface Morphology of microspheres 
The microspheres were studied for shape and 
surface morphology by optical microscopy 
(Olympus, BX 40, Japan) and SEM (Jeol JSM, 
5610 LV, Japan) respectively. Optical 
microscopy was performed by taking small 
amount of microspheres dispersed in water on the 
glass slide and photographs were taken under 40 
X resolution. The SEM studies of chitosan and 
Eudragit coated S 100 coated microspheres were 
carried out by gently sprinkling the powder 
previously kept in a dessicator on the double 
adhesive tape which was fixed on the dies 
followed by application of vacuum and high 
voltage for taking the images under high and low 
resolution. 
 
In vitro Drug Release study from chitosan 
coated microspheres 
In vitro drug release study of coated and uncoated 
chitosan microspheres were performed in pH 
progression medium at 37 0 C ± 0.5 0 C as per 
USP. Release study was further conducted in 
PBS and SCF from 6 -24 hours for coated 
formulation to understand the influence of 
colonic fluid on the release of drug. All 
dissolution studies were performed in triplicate. 
The samples withdrawn at regular intervals of 
time was analyzed using spectrophotometer at 
267nm.    
 
Differential Scanning Calorimetry 
Microspheres containing drug and polymer as 
well as individual ingredients were characterized 
by DSC (Shimadzu, Japan) in the range of 25 – 
350 0 C at a heating range of 100 C per minute 
with an average sample weight of 4 mg. The 
glass transition temperature of polymer as well as 
the presence of any interaction between the drug 
and excipients was characterized.  
 
Organ Distribution Study 
In-vivo drug Distribution Study in GI Tract 
In-vivo drug Distribution Study in gastro-
intestinal tract following oral dosage of 
formulation was conducted in wister rats of either 
sex after due permission from the institutional 
animal ethics committee. Wistar rats were kept in 
well-spaced ventilated cages and maintained on 
healthy and fixed diet. The animals were divided 
into 4 groups of 4 animals each. The first group 
served as control and the other groups were 
treated with a marketed sample (5-FU capsule), 
uncoated crosslinked chitosan microspheres and 
Eudragit S-100 coated microspheres [12]. The 
doses were administered orally with the help of a 
feeding tube and the animals were sacrificed 
humanely after 2, 4, 6, and 8 hour intervals. The 
stomach, small intestine and the colon were 
isolated. These organs were homogenized by 
Micro Tissue Homogenizer (Mac, Mumbai, 
India) with a small amount of PBS (pH 7.4) 
followed by addition of 1 ml of acetonitrile and 
kept for 30 minutes. The contents were 
centrifuged at 1000 rpm for 20 minutes, the 
supernatant liquid was separated and diluted 
appropriately. The drug content in the separated 
liquid was determined using HPLC system 
equipped with a C18 (mu) Bondapak column and 
a UV detector set at 260 nm [13]. The drug 
content in different parts of the GI tract at 
different time intervals was calculated. 
 
Results and Discussion 
Chitosan is a commonly used polymer for the 
preparation of microspheres for varied 
pharmaceutical applications. They are of 
particular importance as mucoadhesive polymers 
due to their positive charge. Chitosan is a 
polysaccharide obtained by the partial alkaline n 
– acetylation of chitin which is a straight chain 
homopolymer composed of n acetyl glucosamine 
units with three dimensional α-helical 
 
 
263
Nayak et al. International Journal of Drug Delivery 3 (2011) 260-268 
 
configuration. Deacetylation of chitin yields a 
linear chain copolymer, chitosan, which is 
comprised of glycosamine and n acetyl 
glycosamine units linked by β (1,4) glycosidic 
bonds. Thus, chitosan degrades in presence of 
colonic enzymes and can act as a suitable carrier 
for colonic drug delivery.  
 
Oral formulation for colonic drug delivery needs 
protection from gastric and intestinal media in 
addition to its degradability in colon. Chitosan 
microspheres thus need enteric coating to protect 
the degradation of the microspheres in acidic 
environment of stomach. In addition, control over 
the release of the entrapped drug in intestine and 
colon is also required to achieve maximum 
availability of the drug in colon. Hence, in the 
present work, cross linked chitosan microspheres 
are prepared and then coated with enteric coating 
polymer eudragit S 100.   
 
Particle Size and Entrapment Efficiency 
Several batches of chitosan microspheres 
prepared using different drug: polymer ratios 
yielded microspheres in the size range between 
61 and 110 μm (Table 1).  The percentage 
entrapment varied between 34 to 66 % depending 
on drug: polymer ratio and the emulsifier 
concentration. With increase in drug: polymer 
ratio, an increase in the entrapment efficiency and 
particle size was observed in 2 phases. D:P ratio 
of 1:2 and 1:3 showed marginal change in the 
entrapment efficiency (34 – 46 %) and particle 
size (61 – 80) while, D:P ratio of 1:4 and 1:5 
recorded entrapment efficiencies in the range 
between 60 – 66 % and particle size between 90 – 
110 microns. These figures demonstrate the 
requirement of D:P ratio in this range for 
satisfactory entrapment efficiency. Hence, D: P 
ratio of 1:5 and emulsifier concentration of 1 ml 
was optimized.  
 
Cross linking with gluteraldehyde 
The above batches of microspheres were 
subjected to crosslinking using gluteraldehyde for 
the purpose of modulating the release behavior. 
Varied concentrations of gluteraldehyde (0.5 – 
1.5 ml of 25 % w / w solution) was used to 
crosslink the optimized batch. Based on the 
percentage drug release, the volume of 
gluteraldehye was optimized at 1 ml. The 
crosslinking process with glutaraldehyde  hardens 
the walls of the microspheres  reducing their 
porosity, resulting slow drug release.  The 
crosslinking bifunctional agents used here bind to 
different reaction sites in the chitosan. The 
aldehyde groups of the glutaraldehyde form 
covalent imine bonds with the amino groups of 
chitosan, due to the resonance established with 
adjacent double ethylenic bonds via a Schiff 
reaction [14] as shown in Figure 1.   
 
 
(Figure reproduced with permission from Ref. [15])  
 
Coating of crosslinked chitosan microspheres  
Cross linked chitosan microspheres were coated 
using Eudragit S 100 to offer protection of the 
microspheres and to resist release of drug in 
stomach and upper small intestine. Eudragit S 
100 is an anionic co polymer of methacrylic acid 
and methyl methacrylate with 1:2 carboxylic acid 
to ester ratio and has pH resistance threshold of 7. 
It shows lower aqueous solubility than Eudragit L 
series. Hence, for the purpose of achieving low 
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release rate in the lower intestine, Eudragit S 100 
was selected. The coating was conducted by 
emulsion solvent evaporation method using core: 
coat ratio of 1:5 until the weight gain achieved 
was sufficient for gastric protection. The 
observed increase in mean particle size after 
coating was from 105.56 ± 0.98 to 389.13 ± 2.08 
for the optimized batch.      
 
In vitro dissolution study 
In vitro dissolution study was conducted to 
understand in-vitro drug release profile of 
uncoated and coated microspheres. The purpose 
of this formulation was to avoid release of drug in 
gastric and upper intestinal region but to release 
the drug slowly in the lower part of the intestine 
maximizing drug concentration in the colon. 
Accordingly, the in-vitro drug release study was 
conducted in pH change method as per USP 
protocol (2 hours in SGF, 2-6 hours in SIF and 6-
24 hours in SCF) and the results are shown in 
Table 2. The immediate release marketed 
formulation showed almost total release in 4 
hours. Release profile from the uncoated 
microspheres was slow but consistent and 
independent of the pH in the dissolution fluid. 
This finding corroborates that cross linking has 
occurred and is responsible in decreasing the drug 
release rate to a significantly low level in 
simulated gastric media. It has also resulted in 
slow drug release throughout the GI tract 
independent of the pH of the media.  Normally, 
free (not crosslinked) chitosan is more soluble in 
acidic media (due to protonation of the free 
amino group) and would preferentially release 
more drug in gastric pH. Aldehydes like 
glutaraldehyde cross links by schiffs reaction thus 
blocking free amino group partially reducing the 
solubility of the cross linked chitosan in acidic 
media showing no preferential release in gastric 
fluid. Drug release kinetics calculated from the 
release profile of uncoated microspheres show 
linearity (time Vs percent drug release plot) with 
R2 value near to unity (0.9903) indicating the 
possibility of zero order kinetics. Nearly 
complete drug release (88 %) in 10 hours 
indicates the need for enteric coating of the 
formulation for colon delivery. Looking at the 
regression equation of the dissolution profile and 
high value of the intercept (16.984), dose 
dumping from the uncoated microspheres is 
evident. Presence of drug on the surface is further 
evidenced and supported by the DSC thermogram 
of the microspheres showing endothermic peaks 
specific to the drug (5 - FU).  
 
 
Table 2 : Kinetic analysis of  5-FU release profile for 
coated and uncoated microspheres in various media. 
Type of 
micro-
sphere 
Media Time 
frame 
Maxi-
mum 
Release 
Regreesion 
equation 
R2 
value 
Uncoated pH 
change 
media 
0-10 
hrs 
88 % y = 
7.4597x + 
16.984 
0.9903 
SGF  0-2 
hrs 
No 
release 
- - 
SIF 3-6 
hrs 
7.9 % Y= 
2.3643X- 
6.1786 
0.9939 
PBS  
(pH 
6.8) 
8-24 
hrs 
95 % Y= 
4.0156X – 
0.6406 
0.9965 
Coated  
 
 
SCF 8-24 
hrs 
97 % Y= 
3.9565X + 
4.0703 
0.9884 
 
 
 
Figure 2: In vitro drug release study of formulations in 
changing pH media and in simulated colon fluid. Drug 
release study was also conducted in PBS from 6 -24 hours 
for coated formulation in order to understand the influence 
of colonic fluid on the drug release profile.  
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Table 3: Comparative organ distribution study of Eudragit S-100 coated microspheres with uncoated 
microspheres and immediate release marketed tablet of 5-FU  
Percentage of the administered estimated at varied time after oral 
administered* 
Formulation Organ 
2 Hours 4 Hours 6 Hours 8 Hours 
Stomach 69.18± 3.45 35.4± 2,53 ND ND 
Small Intestine ND 33.3± 3.42 17.5± 4.35 ND 
Marketed 
immediate 
release tablet 
of 5-FU 
Colon ND ND 41.6± 5.36 29.2± 5.64 
Stomach ND ND ND ND 
Small Intestine ND 64.7± 5.27 67,9± 4.25 22,2± 3.56 
Cross linked 
chitosan 
microspheres Colon ND ND 35.2± 3.21 40.3± 2.58 
Stomach ND ND ND ND 
Small Intestine ND ND 9.4± 1.23 17.8± 2.12 
Eudragit S-100 
coated 
microspheres Colon ND ND 12.5± 2,14 84.4± 2.26 
*All readings are the mean of three readings; ND: Not detected.  
 
Enteric coated microspheres showed no drug 
release in simulated gastric fluid upto 2 hours 
indicating the intactness of the applied coat.  
Dissolution studies were continued for a further 4 
hour period in simulated intestinal media 
showing negligible drug release (8%). Release of 
drug beyond 6 hours in simulated colon fluid 
(SCF) was very substantial with over 95% release 
in 24 hours. The release profile in this region was 
linear with R2 value near to unity (0.9939) 
indicating zero order kinetics of release.  It was 
interesting to observe negligible difference 
between the release profiles of coated 
microspheres in PBS and SCF. This could be due 
to the cross linking of chitosan which did not 
disintegrate under the influence of colon enzymes 
and thus can be stated that the microspheres 
retained their integrity. The release could be by 
diffusion and / or by erosion of the microsphere 
matrix.   
Analyzing the overall drug release profile of the 
coated microspheres, it is evident that the 
microspheres retained their integrity up to 24 
hours releasing the drug slowly and consistently. 
Considering the average transit time for orally 
administered solid formulations (particularly 
small particulates) as approximately 2 hours in 
stomach, 6 to 8 hours in small intestine and up to 
24 hours in colon, Eudragit coated microspheres 
resisted drug release in stomach, released 8-30 % 
in small intestine and the remaining 70 to 92% in 
colon.  
In-vivo drug Distribution Study in GI Tract  
Drug distribution study in GI tract following oral 
administration of the optimized formulation was 
performed in male wistar rats in order to establish 
the targeting potential to colon. The results of the 
study conducted with marketed oral tablet of 5-
FU, un-coated cross linked chitosan microspheres 
and Eudragit S-100 coated microspheres are 
given in Table 3 and graphically represented in 
Figure 3. The marketed immediate release 
formulation (Capsule) released maximum (69.18 
%) concentration of 5-FU in stomach within 2 
hours of oral administration. After four hours, the 
concentration in stomach and small intestine was 
almost equal (~ 35%) while the concentration of 
the drug after 6 hours and 8 hours in colon was  
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Figure 3: Comparative organ distribution study of Eudragit S-100 coated microspheres, the uncoated microspheres and 
immediate release marketed tablet of 5-FU conducted on wister rat model. The formulations were orally fed to the groups of 
animals (12 animals per formulation). After 2, 4, 6 and 8 hours, group of four animals were randomly sacrificed, stomach, Small 
intestine and colon were isolated, homogenized and the drug content were determined. Average of four readings with SE were 
recorded and tabulated. 
 
 
around 40% and 30% respectively. The uncoated 
cross linked chitosan microspheres failed to 
release the drug in the first 2 hours in the G I 
tract. However, it exhibited a substantial drug 
release in small intestine after 4 hours (64%) and 
6 hours (67 %) but released only about 35 and 40 
% in colon at the end of 8 hours. Eudragit S-100 
coated microspheres showed no drug release up 
to 6 hours in any part of the gastro-intestinal tract 
but showed a substantial drug release in colon at 
8 hours (~84 %). The results indicate the 
intactness of the coated microspheres in the upper 
part of the GI tract followed by negligible drug 
release (6% to 8%)    during its transit through the 
upper GI tract (2-6 hours) and may possibly be 
due to the leaching process. After 6 to 8 hours, 
maximum percentage of drug was observed in 
colon with no drug present in the stomach and a 
very small amount found in the small intestine. 
 
Conclusions 
The results of the present study indicate the 
potential of Eudragit S – 100 coated cross linked 
chitosan microspheres in designing site-specific 
delivery for treating colon related disorders for 5-
FU. The investigations of different parameters 
involved in preparation of coated system proved 
that the method is simple and reproducible. The 
particle size and coat integrity can be controlled 
and monitored for releasing the drug within the 
affected / targeted area. In vitro drug release 
experiments with uncoated cross linked chitosan 
microspheres showed no drug release in SGF, 
nearly complete drug release in SIF and very low 
drug release in SCF. Eudragit S – 100 coated 
microspheres showed no release in SGF, 
negligible release in SIF and maximum release in 
colonic media. The in-vitro observation was 
found to be in correlation with in-vivo drug 
distribution studies in GIT conducted in rats 
wherein about 84% of the drug detected was in 
colon. Thus, the designed formulation was found 
suitable for colon delivery which resists drug 
release in stomach and in upper small intestine 
but can release maximum amount of drug in 
colon.    
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